- Home
- SGC vs GNFT Comparison
SGC vs GNFT Comparison
Compare SGC & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- GNFT
- Stock Information
- Founded
- SGC 1920
- GNFT 1999
- Country
- SGC United States
- GNFT France
- Employees
- SGC N/A
- GNFT N/A
- Industry
- SGC Apparel
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGC Consumer Discretionary
- GNFT Health Care
- Exchange
- SGC Nasdaq
- GNFT Nasdaq
- Market Cap
- SGC 202.3M
- GNFT 186.3M
- IPO Year
- SGC N/A
- GNFT 2019
- Fundamental
- Price
- SGC $13.01
- GNFT $4.38
- Analyst Decision
- SGC Strong Buy
- GNFT Strong Buy
- Analyst Count
- SGC 3
- GNFT 2
- Target Price
- SGC $17.33
- GNFT $11.00
- AVG Volume (30 Days)
- SGC 44.8K
- GNFT 3.8K
- Earning Date
- SGC 08-05-2025
- GNFT 09-18-2025
- Dividend Yield
- SGC 4.31%
- GNFT N/A
- EPS Growth
- SGC N/A
- GNFT N/A
- EPS
- SGC 0.52
- GNFT 0.03
- Revenue
- SGC $576,240,000.00
- GNFT $73,187,701.00
- Revenue This Year
- SGC N/A
- GNFT $5.15
- Revenue Next Year
- SGC $4.31
- GNFT N/A
- P/E Ratio
- SGC $24.91
- GNFT $141.71
- Revenue Growth
- SGC 4.03
- GNFT 105.01
- 52 Week Low
- SGC $9.11
- GNFT $2.55
- 52 Week High
- SGC $18.48
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SGC 66.11
- GNFT 59.65
- Support Level
- SGC $11.91
- GNFT $4.12
- Resistance Level
- SGC $12.87
- GNFT $4.62
- Average True Range (ATR)
- SGC 0.67
- GNFT 0.17
- MACD
- SGC 0.13
- GNFT 0.05
- Stochastic Oscillator
- SGC 94.04
- GNFT 73.77
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.